VOLUME 20 | NUMBER 11 | NOVEMBER 2017 nature neurOSCIenCe a r t I C l e S Transcriptional control of gene expression is regulated at several levels, including site-specific transcription factors, epigenetic modifications of chromatin, and long-range enhancer interactions [1] [2] [3] . Understanding how these diverse regulatory layers coordinate gene expression in three dimensions across long-range enhancers to influence biological phenomena remains a fundamental question with critical implications for development, physiology, and associated diseases. Embryonic stem cells and the hematopoietic system have provided useful initial insights into how three-dimensional chromatin configurations are formed and regulate gene expression in vertebrates [4] [5] [6] [7] [8] [9] . Despite these advances, how long-range enhancers and associated three-dimensional chromatin architecture contribute to the development of the CNS and associated diseases remains unclear.
a r t I C l e S
Transcriptional control of gene expression is regulated at several levels, including site-specific transcription factors, epigenetic modifications of chromatin, and long-range enhancer interactions [1] [2] [3] . Understanding how these diverse regulatory layers coordinate gene expression in three dimensions across long-range enhancers to influence biological phenomena remains a fundamental question with critical implications for development, physiology, and associated diseases. Embryonic stem cells and the hematopoietic system have provided useful initial insights into how three-dimensional chromatin configurations are formed and regulate gene expression in vertebrates [4] [5] [6] [7] [8] [9] . Despite these advances, how long-range enhancers and associated three-dimensional chromatin architecture contribute to the development of the CNS and associated diseases remains unclear.
Decoding transcriptional regulation via three-dimensional architecture requires the identification and validation of distal enhancers that regulate long-range regulation of gene expression 10 . This represents a major barrier: the in silico approaches currently used can predict enhancer function, but these activities can vary across dynamic developmental states and cell lineage, ultimately requiring validation in appropriate in vivo models 11, 12 . These limitations highlight the need for tractable in vivo systems to identify and validate enhancer elements, as these are key entry points for understanding how chromatin architecture influences gene expression and, more broadly, tissue development and disease.
The developing spinal cord offers an attractive system in which to identify enhancers and investigate these regulatory mechanisms in vivo, as it is an accessible embryonic tissue containing diverse CNS lineages that are generated in a well-defined spatial and temporal pattern 13, 14 . One of the key events that occurs during spinal cord development is a process termed the 'gliogenic switch' [14] [15] [16] . Initially, progenitor populations produce neurons between embryonic day (E) 3-E5 (E9-E11 in mouse) and subsequently produce glia beginning at E6 (E12 in mouse). Previously, we identified nuclear factor I-A (NFIA) as a key transcriptional determinant of the gliogenic switch, in which NFIA is induced in progenitor populations coincident with the onset of gliogenesis 17, 18 . Sox9 (sex-determining region Y-box 9) directly regulates NFIA induction, but expression of NFIA is only mildly affected in the absence of Sox9 and NFIA is also expressed in motor neuron populations in the spinal cord, suggesting that additional regulatory elements regulate NFIA expression across neuronal and glial lineages during development 18 .
To delineate these regulatory mechanisms, we performed an enhancer screen in embryonic chick spinal cord and identified multiple long-range enhancer elements that recapitulate NFIA expression in glial precursors and motor neurons. Chromatin conformation and genetic analysis revealed distinct chromatin architectures and associated transcriptional mechanisms regulating NFIA expression across glial and neuronal lineages. These chromatin architectures are a r t I C l e S present in glioma and regulate NFIA expression and tumorigenesis through the associated enhancers. Together, our multidisciplinary approach, integrating in vivo enhancer discovery and long-range chromatin interactions with mouse genetics and associated disease models, defines a transcriptional mechanism that regulates CNS development and malignancy.
RESULTS
NFIA enhancers demonstrate lineage-specific activities and regulation NFIA is specifically induced in glial precursors occupying the ventricular zone (VZ) and in motor neurons in mantel regions during the E4-E6 gliogenic switch interval in the embryonic chick spinal cord (Fig. 1a,b) . That NFIA demonstrates expression across diverse CNS lineages raises the question of how it is selectively regulated within these cell populations. To identify the transcriptional mechanisms associated with its expression in the spinal cord, we performed an enhancer screen in embryonic chicks and identified an enhancer termed e161 that recapitulates the spatial and temporal patterns of NFIA induction in glial progenitors of the VZ (Fig. 1e ,f,u and Supplementary Figs. 1 and 2). Subsequent overexpression and deletion mapping studies revealed that Brn2 (also known as Pou3f2) regulates the activity of e161 ( Fig. 1i -n,v,y,z and Supplementary Fig. 2 ). Our previous studies identified the e123 enhancer, which is regulated by Sox9 and has a spatiotemporal pattern of activity similar to that of e161 18 (Fig. 1c,d,o) . Therefore, we next investigated the specificity of the e123-Sox9 and e161-Brn2 regulatory relationships and found that Sox9 and Brn2 did not cross-activate enhancers (Fig. 1l,p) , suggesting that these are distinct regulatory nodes that collaboratively oversee NFIA induction during gliogenesis.
In the course of screening our candidate enhancers, we identified another element, e96, which is specifically active in motor neurons (MNs; Fig. 1g,h ) and resembles NFIA expression in these populations (Fig. 1b) . Deletion mapping and overexpression studies revealed that Isl1 and Lhx3, transcriptional partners required for MN development 19, 20 , regulate the activity of e96 (Fig. 1t,v-x; Supplementary  Fig. 3 ). Moreover, Sox9 and Brn2 do not activate e96, and Isl1 and Lhx3 do not activate e123 and e161 ( Fig. 1i-t) , suggesting that regulation of the enhancers by these transcription factors is lineage-specific. Put together, our enhancer studies suggest that distinct transcriptional mechanisms regulate NFIA expression across CNS lineages: Sox9 and Brn2 in glial precursors and Isl1 and Lhx3 in MNs.
Lineage-specific transcriptional mechanisms regulate NFIA expression We next sought to determine whether the individual transcriptional mechanisms implicated by the enhancer studies regulate NFIA expression in glial precursors or motor neurons. The e123 and e161 enhancer studies suggest that Sox9 and Brn2 collaboratively regulate NFIA induction during the gliogenic switch. In support of this model, we found that Sox9 and Brn2 were co-expressed in VZ populations at E12.5 in the mouse, concurrent with NFIA induction (Fig. 2a,b ,e,i). To examine this putative relationship at the genetic level, we evaluated NFIA induction during the gliogenic switch in a series of Sox9 and Brn2 single-and double-mutant mice 21, 22 ( Supplementary Fig. 4 ). Analysis of Sox9 or Brn2 single-mutant mice revealed a delay in NFIA induction at E11.5 ( Fig. 2e-g ) and reduced expression at E12.5 ( Fig. 2i-k) , suggesting compensation by other Sox-or Pou-family members. The Sox9;Brn2 double-mutant demonstrated delayed induction at E11.5, which continued through E12.5 and was matched by a concordant reduction in the expression of the glial precursor marker Glast (Fig. 2h,l-p and Supplementary Fig. 4 ). That the double Sox9;Brn2 mutants demonstrated a substantially greater reduction in NFIA expression compared to the single mutants ( Fig. 2j-l) indicates that genetic cooperation between these factors regulates a r t I C l e S NFIA induction during the gliogenic switch. To further understand the nature of the collaboration between Sox9 and Brn2, we examined whether there was also a biochemical relationship. We performed co-immunoprecipitation (co-IP) studies on mouse E12.5 spinal cord, finding that Sox9 and Brn2 associate in these tissues ( Fig. 2c and Supplementary Fig. 4 ), suggesting that cooperation between these factors is mediated at the biochemical level.
In parallel, we investigated the regulatory relationship between Isl1 and NFIA in MN populations, finding that they were co-expressed in MNs at E12.5 in the spinal cord (Supplementary Fig. 4) . Examination of their genetic relationship revealed that Isl1 mutants demonstrated a robust decrease in NFIA expression in the MN populations, where there was a drastic decrease in the number of Lhx3 + cells that coexpressed NFIA (Fig. 2q-s) . These observations in MNs, coupled with our findings during the gliogenic switch, support a model whereby distinct transcriptional mechanisms regulate NFIA expression in MNs and glial precursors.
NFIA enhancers form distinct chromatin architectures in the spinal cord Having established the genetic relationships that oversee NFIA induction in glial precursors and MNs, we next sought to determine the biochemical mechanism by which these regulatory relationships operate. Focusing first on the Sox9-Brn2 relationship in glial precursors, the relative locations of the associated e123 and e161 enhancers gave critical insight into the putative mechanism of action. In the mouse, e123 is 90 kb away from the transcriptional start site (TSS) and 120 kb from the e161 enhancer (Fig. 3a) , while the e161 enhancer is 30 kb from the TSS and is located within the first intron (Fig. 3a) . These data, coupled with our co-IP data, suggest that long-range DNA interactions between e123 and/or e161 and the TSS are responsible for NFIA induction during the gliogenic switch. To test this possibility, we performed chromatin conformation capture (3C) 23, 24 on E12.5 spinal cord to test the long-range DNA interactions between e123, e161, and the TSS-promoter across the encompassing 120-kb interval within the NFIA locus (Fig. 3a) . Using e123 as our anchor point for 3C, we identified strong associations with the region in close proximity to the TSS-promoter region (region 6) and with the region containing e161 (region 11) that were not present in other NFIA-expressing tissues such as lung (Fig. 3b) . To further substantiate these interactions, we performed chromatin immunoprecipitation (ChIP) analysis on E12.5 spinal cord, finding that both Sox9 and Brn2 associated with their response sites within e123 and e161, respectively, as well as with the TSS region, but not with e96 ( Fig. 3d and Supplementary  Fig. 5 ). Integration of these 3C and ChIP data, along with our co-IP observations (Fig. 2c) suggests a double-looped conformation across the e123-TSS-e161 interval at the NFIA locus during the gliogenic switch in the spinal cord (E11.5-E12.5; Fig. 3c) . Notably, given that NFIA induction is delayed in the Sox9 and Brn2 single-mutants ( Fig. 2i-l) , it is likely other, compensatory Sox-and/or Pou-family members can also participate in this looped configuration under those specific genetic conditions. Next, we addressed the mechanism by which Isl1 and Lhx3 regulate the expression of NFIA in MNs. Like the gliogenic enhancers, e96 is a long-range enhancer element, as it lies approximately 135 kb away from the TSS (Fig. 3a) . Using the TSS as the anchor point, we performed 3C assays on E12.5 spinal cord, finding a strong association between the TSS and regions containing e96 (region 14) and that the associations between the TSS-promoter and e96 were not present in other NFIA + tissues such as lung (Fig. 3e) . ChIP assays on E12.5 spinal cord confirmed association of both Isl1 and Lhx3 with e96 and the TSS, but not with e123 or e161 ( Fig. 3g and Supplementary  Fig. 5 ). These data, coupled with our 3C data, suggest a single looped conformation across the e96-TSS interval at the NFIA locus during the gliogenic switch in the spinal cord. (Fig. 3f) . These data, combined with our observations from the gliogenic enhancers, provide genetic, biochemical, and three-dimensional conformational evidence that differential chromatin looping at the NFIA locus drives its expression across diverse CNS lineages in the developing spinal cord (Fig. 3c,f) . Figure 10 for uncropped images of gels in d.
a r t I C l e S Gliogenic chromatin architecture forms before NFIA induction To further understand the properties of these NFIA-associated chromatin loops, we focused on the gliogenic chromatin loop and investigated whether this chromatin architecture is regulated by the associated transcription factors, Sox9 and Brn2. Given the difficulty of breeding a sufficient number of Sox9;Brn2 double-mutant embryos in which to perform 3C, coupled with possible redundancy with other Sox-and Pou-family members, we addressed this question by using the Hb9-GFP reporter mouse. This mouse line allows us to use GFP expression in MNs to physically dissect MN populations from VZ populations in the E12.5 spinal cord, such that the GFP − VZ populations contain Sox9 and Brn2 while the GFP + MN populations do not (Fig. 4a) . In this way we can assess gliogenic loop formation in cell populations that express Sox9 and Brn2, as well as in those that do not. As shown in Figure 4b , the e123 and e161 chromatin configuration is present in both GFP − and GFP + cell populations in the E12.5 spinal cord. The presence of the gliogenic loop in GFP + populations that lack Sox9 and Brn2 expression suggests that its formation occurs independent of these factors. One feature of many chromatin loops that regulate gene expression during development is that they form before the induction of the target gene and are, therefore, considered 'preformed' loops 25 . These preformed structures are thought to provide a permissive configuration through which tissue-specific transcription factors provide timely responses to developmental stimuli 26 . That the NFIA gliogenic loop forms independent of Sox9 and Brn2 suggests that it may also be a preformed loop. To evaluate whether this is indeed the case, we determined whether the NFIA gliogenic loop was present before NFIA induction at E10.5 and after its induction at E16.5. As shown in Figure 4c ,d, the gliogenic loop is found at both E10.5 and E16.5, indicating that it is preformed at E10.5 and stable across early glial development.
That the gliogenic chromatin loop is preformed before NFIA induction at E10.5 raises the question of how NFIA is induced at E11.5. Given that formation of the loop does not require Sox9 or Brn2, yet these factors are required for NFIA expression (Fig. 2) , one possibility is that these transcription factors are not able to bind their respective enhancers at E10.5. To test this possibility, we performed ChIP assays on E10.5 spinal cord, assessing the association between Sox9 or Brn2 and e123, e161, or promoter regions, respectively. These experiments revealed that Sox9 and Brn2 do not efficiently immunoprecipitate with the e123, e161, and promoter regions at E10.5, yet these factors efficiently associate with these regulatory elements at E12.5 ( Fig. 4e,f) . One potential explanation for this shift in enhancer occupancy by Sox9 and Brn2 is changes in chromatin state, which we assessed via ChIP + qualitative PCR on E10.5 and E12.5 spinal cord using antibodies for poised (or silent) enhancers (H3K4me1 + H3K27me3) and active enhancers (H3K4me1 + H3K14Ac). We found that both e123 and e161 enhancers contain chromatin marks consistent with poised/silent chromatin at E10.5 and that these marks (H3K27me3) are dramatically reduced at E12.5 ( Fig. 4g,h ). These changes likely reflect the acquisition of a more permissive chromatin state at E12.5, which allows Sox9 and Brn2 to bind to their respective enhancers. In parallel, we also found a concordant increase in active chromatin, reflected by an increase in H3K14Ac marks across the E10.5-E12.5 interval. Together, these data indicate that the gliogenic 3C assay performed on E12.5 spinal cord from Hb9-GFP mice, where the GFP + MN and GFP − VZ regions were manually dissected. e123 (red) was the anchor point from which long-range DNA interactions across the e123-e161 interval were measured. (c,d) 3C assay performed on E10.5 (c) and E16.5 (d) spinal cord from wild-type mice. e123 (red) was the anchor point from which long-range DNA interactions across the e123-e161 interval were measured. For each 3C experiment (b-d), three independent libraries were assayed per experiment. Note that in each 3C experiment a no-ligase control was performed to assess the level of ligase-independent nonspecific PCR products. Numbers over the data points represent fragment location. (e,f) ChIP assays on E10.5 and E12.5 spinal cord, comparing the relative enrichment of Sox9 (e) and Brn2 (f) associations with e123, e161, and the core promoter. (g,h) ChIP assays from spinal cord comparing the methylation and acetylation status of the E123 and E161 enhancers before (E10.5) and during the gliogenic switch (E12.5). Blue-shaded panels represent data from e123 at both E10.5 and E12.5, while pink-shaded panels represent data from e161 at both E10.5 and E12.5. Statistics: in e-h, error bars indicate standard deviation; and results of two-tailed t tests are shown; in e, *P = 0.03, **P = 0.04, and ***P = 0.007. In f, *P = 9 × 10 −5 , **P = 0.004, and ***P = 0.05. In h, *P = 0.01 and **P = 0.04. All error bars are s.d. Scale bar, 100 µm. a r t I C l e S loop is formed before NFIA induction and that the precise timing of NFIA induction is further coordinated by the specific association of Sox9 and Brn2 with their enhancers during the gliogenic switch.
Glia-specific enhancers regulate NFIA expression and tumorigenesis Given that developmental processes are often reutilized during tumorigenesis, we sought to determine whether similar regulatory mechanisms are associated with NFIA expression in glioma 27, 28 . Taking a bioinformatics approach, we assessed the co-expression of NFIA with its associated transcriptional regulators across a cohort of >400 high-grade human glioma expression datasets 29 . Using Spearman's correlation co-efficiency analysis, we found that NFIA expression is very highly correlated with both Sox9 and Brn2 but not with Lhx3 and Isl1 (Fig. 5a-c and Supplementary Fig. 6 ). These relationships were corroborated in additional glioma datasets comprised of both highand low-grade gliomas (Supplementary Fig. 6 ) 30 , and together they suggest that the transcriptional mechanisms controlling NFIA expression during gliogenesis similarly regulate its expression in glioma. To test this hypothesis, we used two different mouse models of glioma that harness in utero electroporation (IUE) of the embryonic cortex to facilitate gene manipulation. One model utilizes CRISPR/Cas9 (CRISPR/IUE) 31 gene editing of NF1, PTEN, and p53, tumor suppressors that are commonly mutated in human glioma [32] [33] [34] , while the other utilizes PiggyBac (PB) targeting of glial lineages with oncogenic Ras to produce malignant glioma 28, 35 (PB-Ras/IUE; Supplementary  Fig. 7) . Mutations in Ras are rare in glioma, but EGFR, PDGFR, and NF1 are frequently mutated, and all of these pathways signal through Ras. Therefore, while Ras itself is not directly mutated, the pathway is frequently hyperactivated in glioma and can be used as a surrogate for mutation of these key glioma-associated pathways.
Analysis of tumors from our mouse models revealed extensive co-expression of NFIA with Sox9 and Brn2, with nominal expression of Isl1 and Lhx3, indicating that these models reflect these features of human glioma (Supplementary Fig. 8) . Next, to determine whether NFIA is similarly regulated in glioma, we interrogated the threedimensional conformation of the e123-TSS-e161 interval within the NFIA locus in both the CRISPR/IUE and PB-Ras/IUE glioma models using 3C. As indicated in Figure 5d ,e, the e123 anchor demonstrated a strong association with regions in close proximity to the TSS-promoter region (region 6) and the region containing e161 (region 11), indicating that the NFIA locus in both glioma models demonstrates a three-dimensional conformation that parallels developmental gliogenesis (Fig. 3b) .
The above observations suggest that NFIA expression in glioma is governed by the e123-Sox9 and e161-Brn2 regulatory axis and the long-range interactions between these enhancer elements. To directly test whether these interactions and the resulting three dimensional conformation of the NFIA locus are required for its expression in our glioma model, we turned to CRISPR-mediated gene editing to delete the e123 and e161 enhancers 36, 37 . We generated guide RNAs that efficiently targeted regions surrounding the conserved Sox9 and Brn2 response sites in the mouse e123 and e161 enhancers (Fig. 6u,  Supplementary Fig. 9 , and Online Methods). We used the PB-Ras/IUE Fig. 6 ). (d,e) 3C assay performed on CRISPR/IUE generated tumors at postnatal day (P) 70 (d) and PB-Ras-generated glioma tumors at P14 (e). In both cases, e123 (red) was the anchor point from which long-range DNA interactions across the e123-e161 interval in these tumors were measured. Numbers over the data points in d and e represent fragment location.
a r t I C l e S model to test the contributions of these enhancers, because tumors are produced 2-3 weeks after birth, making it a tractable model system in which to determine whether deletions of these enhancers influence NFIA expression and tumor growth. As indicated in Figure 6a -y, introduction of the guide RNAs and CAS9 to both e123 and e161 resulted in decreased rate of gross tumor growth (Fig. 6v) , cell proliferation (Fig. 6w) , and loss of NFIA expression within the tumor ( Fig. 6x ; see also Supplementary Fig. 8) ; efficient deletion of the targeted e123 and e161 regions within the tumor was confirmed via deep sequencing ( Supplementary Fig. 9 and Online Methods). These effects on NFIA expression and tumor growth were not secondary to reduced expression of Sox9 and Brn2 within the tumor, as their expression remained unchanged in the presence of e123 and e161 guide RNAs (Supplementary Fig. 8 ). Finally, introduction of single e123 or e161 guide RNAs did not impact tumor growth or NFIA expression (Fig. 6k-t and Supplementary Fig. 8 ).
That CRISPR-mediated deletion of response sites within e123 and e161 resulted in decreased NFIA expression and tumor growth in the presence of normal levels of Sox9 and Brn2 suggests that the threedimensional conformation of the e123-TSS-e161 interval within the NFIA locus was disrupted. To test this, we performed 3C on tumors generated in the presence of the e123 and e161 guide RNAs and found that the long range interactions between the e123 anchor point and the TSS-promoter region (region 6) were disrupted, while the interaction with e161 (region 11) was significantly reduced (Fig. 6y) . These data, in conjunction with our phenotypic analysis of glioma formation, indicate that the three dimensional conformation of the e123-TSS-e161 interval within the NFIA locus is essential for NFIA expression in glioma and tumorigenesis.
DISCUSSION
Leveraging insight gained from the in vivo validation of enhancer elements during the gliogenic switch in the chick, we used a combination of genetic, biochemical, and 3C approaches to identify lineagespecific chromatin looping mechanisms that regulate expression of NFIA in the developing CNS. These studies delineate a comprehensive three-dimensional chromatin regulatory mechanism in the developing CNS and demonstrate that the chromatin architecture and associated regulatory mechanisms for the same gene can vary between cell lineages in vivo (Fig. 3) .
Dissection of these lineage specific processes identified Brn2 and Isl1 or Lhx3 as transcription factors for NFIA induction in glial precursors (w,x) Quantification of Ki67 (w) and NFIA (x) in P14 PB-Ras tumors with e123-and e161-deletion and control animals. (y) 3C assay performed on PB-Ras-generated glioma tumors that were subjected to CRISPR-mediated gene editing of the response regions within e123 and e161. e123 (red) was the anchor point from which long-range DNA interactions were measured. Three independent libraries were assayed per experiment. In v-y error bars indicate s.d., and results of two-tailed t tests are shown. In y, *P = 0.0001272 and **P = 0.0001962. In v: ANOVA *P = 0.0001; t test, P = 0.003. In w: *P = 0.0049. Scale bars, 100 µm. px330, standard plasmid backbone into which the guide RNAs are cloned. a r t I C l e S and MNs, respectively. Brn2 is a member of the POU family of transcription factors and has been implicated in the migration of cortical neurons and reprogramming of induced pluripotent stem cells to the neuronal lineage 22, [38] [39] [40] , but its role in glial lineage development has not been characterized. Our genetic and biochemical studies implicate Brn2 expression and its association with Sox9 as key events during the initiation of gliogenesis in the spinal cord. Indeed, cooperative gene regulation between Sox-and POU-family members has been observed in a wide range of tissues and model systems, suggesting that it is a more general transcriptional mechanism [41] [42] [43] . While expression and function of NFIA in glial progenitors has been well studied, its role in motor neurons has remained undefined. Our studies reveal that key regulators of motor neuron development, Isl1 and Lhx3, directly regulate NFIA expression, suggesting that NFIA may participate in the well-described transcriptional networks regulating motor neuron development and physiology 44 . While motor neurons do not demonstrate any overt developmental defects in the absence of NFIA (data not shown), additional genetic, biochemical, and physiological analyses in these populations will be required to explore this in more detail.
Our genetic studies indicate that selective NFIA expression in glial precursors and MNs is regulated by the expression of these cell fate determinants in the associated populations. Sox9 and Brn2 regulate NFIA expression in the VZ, while Isl1 and Lhx3 regulate NFIA expression in MNs. Further examination of this phenomenon revealed that these factors and associated enhancers form specific chromatin configurations across the NFIA genomic locus. Moreover, we found that the gliogenic chromatin conformation forms before NFIA induction and its formation does not require Sox9 or Brn2. These preformed loops are thought to create a permissive configuration that facilitates transcription factor associations, enabling timely gene induction during dynamic developmental states. In this case, the preformed gliogenic loop serves to facilitate the association between Sox9 and Brn2, which drives gliogenic expression of NFIA. Given that Sox-and Pou-family members associate and cooperate to drive gene expression across numerous systems, it is possible that preformed chromatin loops are a conserved mechanism that engenders cooperation between these transcription factor families in other tissues.
Additional studies on the timing of NFIA induction revealed that Sox9 and Brn2 do not immunoprecipitate with the e123 and e161 regulatory elements at E10.5, further reinforcing our observation that the gliogenic loop is preformed. These data lead to a model in which the gliogenic loop forms but cannot activate gene transcription until the timely association of Sox9 and Brn2 with the e123 and e161 elements after E10.5. Association of Sox9 and Brn2 with their respective enhancers is likely mediated by changes in chromatin state, as both e123 and e161 demonstrate drastic reductions in silent/poised chromatin marks across the E10.5-E12.5 interval that are correlated with Sox9 and Brn2 binding (Fig. 4e-h ). These data suggest that additional epigenetic regulators are likely to be involved in the induction of NFIA. Moreover, that both e123 and e161 demonstrate coordinated changes in epigenetic states further reinforces the utility of the preformed chromatin loop at E10.5 as a key facilitator of these inductive events across long distances.
In addition to epigenetic mechanisms, these observations also suggest specific interactions between Sox9 or Brn2 and the transcriptional mechanisms that oversee chromatin looping. Recent studies using 3C in embryonic stem cells identified Med12 as a key regulator of chromatin looping that operates at the core promoter and functions to maintain embryonic stem cells in an undifferentiated state 8 . Notably, in other tissues and model systems, Sox9 associates with Med12 and functions as its co-activator [45] [46] [47] . Moreover, Sox10 has been shown to also interact with Med12 and facilitate the recruitment of the mediator complex in Schwann cells 48 , suggesting that Sox proteins may serve as transcriptional interfaces with factors regulating chromatin architecture. It will be useful to further dissect how these factors selectively interface with established components of the chromatin looping machinery (i.e., CTCF (CCCTC binding factor), mediator, cohesion) 8 .
Using these developmental processes to gain insight into malignant glioma, we found that the NFIA locus in glioma demonstrates a similar chromatin conformation to that found in glial precursors (Fig. 4) . Strikingly, CRISPR-mediated deletion of both the e123 and e161 enhancers resulted in decreased tumor growth, decreased NFIA expression, and disrupted chromatin conformation. That tumor growth was attenuated when NFIA expression was reduced in the absence of e123 and e161 is consistent with other studies demonstrating that it plays multiple key roles in glioma proliferation and tumorigenesis 27, 28, 49 . In mouse glioma stem cells and in human cell line xenograft models, NFIA regulates cell proliferation via repression of p21, whereas in an IUE-based model of oligodendroglioma, NFIA influences the generation of glioma 'fates' or subtypes 29, 30 . Consistent with a role for NFIA in glioma tumor cell proliferation, we found a significant decrease in cell proliferation when both e123 and e161 were deleted (Fig. 6v,w) . Notably, while our findings further implicate NFIA in glioma tumorigenesis, additional genetic studies are necessary to definitely prove that NFIA itself is required for glioma tumorigenesis, as our experiments indirectly manipulated NFIA expression via its associated enhancer elements.
Nevertheless, these results do provide direct evidence that the e123 and e161 enhancers are essential for NFIA expression and, more broadly, implicate the architecture of the NFIA locus as a key regulator of gliogenesis and glioma tumorigenesis. That CRISPR-targeted deletion of 123 and e161 did not result in a complete elimination of NFIA expression is likely due to incomplete deletion of the enhancers (Fig. 6x and Supplementary Fig. 9 ). Other possibilities include infiltrating non-tumor-derived reactive astrocytes that express NFIA and the presence of other, undefined, long-range enhancers that oversee its expression. Notably, deletion of individual e123 or e161 enhancers did not affect NFIA expression, suggesting that Sox9 and Brn2 were able to associate in the presence of just one enhancer and that this association was sufficient for the synergistic activities of this complex to drive NFIA expression. Alternatively, in the context of tumorigenesis, individual expression of Sox9 or Brn2 may be sufficient to drive NFIA expression.
Despite these possibilities, our chromatin looping studies strongly suggest a cooperative mechanism of action between Sox9 and Brn2 in glioma. Moreover, given our previous findings that Sox9 and NFIA cooperate 18 , it is possible that NFIA itself is a part of this transcriptional regulatory node for glioma tumorigenesis. Along these same lines, previous studies found that Brn2, Sox2, Olig2, and Sall2 comprise a key transcriptional node in glioma stem cell systems 50 . Given that NFIA and Sox9 interact with each other and modulate Olig2 function 28 , it is likely that they are also a part of this broader developmental transcriptional regulatory node operating in glioma stem cells. Alternatively, given that Sox9 and NFIA both antagonize Olig2 function, it may be that they function in glioma cell lineages downstream of stem cells to promote differentiation into pathological glia, which, we note, comprise the vast majority of the bulk tumor. Indeed, our recent studies have identified several astrocyte-like subpopulations of cells within mouse and human glioma 31 , and it may be that the NFIA-Sox9-Brn2 node functions to promote the differentiation of a r t I C l e S these populations during tumorigenesis. Future studies will be aimed at understanding the roles of Sox9, NFIA, and Brn2 in glioma stem cells, how these new transcriptional nodes influence the production of diverse glioma cell populations, and the nature of their relationship with the glioma stem cell transcriptional node.
In many respects, tumorigenesis is, in part, a recapitulation of development. Our study has identified a transcriptional mechanism that oversees the induction of a key glial fate determinant, NFIA. Critically, this mechanism is reutilized during glioma tumorigenesis and plays a critical role in tumor formation. The broad implications from these findings are that, along with raw expression profiles and epigenetic characteristics, the antecedent 3D-chromatin architectures of key regulatory factors are also conserved across developmental lineages implicated in malignancy.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METhODS
enhancer screen and chick in ovo electroporation. The enhancer screen was performed by comparing genomic sequence 100 kb upstream and downstream of the mouse and chick NFIA transcriptional start sites using ECR browser software (https://ecrbrowser.dcode.org). Each black line represented in Figure 1a represents a conserved genomic region between 100 and 300 bp in length that is (roughly) < 70% conserved from mouse and chick. There are 35 such regions in 13 clusters across this 200-kb interval. Each of these conservation clusters was considered a candidate enhancer region; each of these 13 putative enhancers is denoted by the red box in Figure 1a . These prospective enhancers were cloned from chick genomic DNA (including ±1 kb from the clusters) into a PCR 2.1 TOPO cloning kit (ThermoFisher Scientific) containing a minimal promoter and a GFP reporter. Putative enhancers were assayed using the chick in ovo electroporation system, in which reporter constructs were injected into the lumen of the neural tube of HH stage 12-14 chick embryos (E2) and then electroporated. Electroporation efficiency was monitored by co-injection of an expression vector containing mCherry. Electroporation was carried out with a BTX Electro Square Porator. Harvested embryos were fixed in 4% formaldehyde for 1-3 h, depending on stage, or processed for biochemical experiments. Reporter constructs demonstrating appropriate spatiotemporal expression patterns were further analyzed. We screened a total of 13 candidate enhancers (six upstream, seven intronic). We found that e123 and e161 had activity in gliogenic VZ and e96 had activity in MN populations. Putative transcription factor binding sites contained within enhancer elements were evaluated by the ChIP MAPPER search engine (http:// genome.ufl.edu/mapper/), which uses the TRANSFAC and JASPAR models to predict transcription factor binding sites. Putative transcription factor sites within a given DNA sequence that scored >3 were considered for further evaluation. Additional chick expression constructs were cloned into RCAS(B) or PCS2. Immunohistochemistry/in situ hybridization. Briefly, embryos were harvested and fixed in 4% formaldehyde, cryoprotected with 20% sucrose overnight, embedded in O.C.T. compound (Tissue-Tek), and cryosectioned at 18 µm. In situ hybridization on frozen embryos was performed as previously described 17 . To detect the expression of GLAST and FABP7, we generated mRNA probes and performed in situ hybridization on mouse spinal cord and mouse glioma. To generate probes, pCMV-SPORT6 containing cDNAs was used. An zntisense probe was produced by T7 RNA polymerase followed by Sal1 enzyme digestion. The sense probe was generated by SP6 RNA polymerase followed by Not1 enzyme digestion. To apply ISH on human TMA, the tissue array was first deparaffinized by xylene, 100% EtOH, 90% EtOH, 70% EtOH, and 50% EtOH, twice each for 5 min per step. Deproteinization was then conducted using proteinase K (10 µg/mL) for 5min, 4% PFA for 15min, 0.25% acetic anhydride in 0.1 M triethanolamine for 5 min; between steps samples were washed with PBS for 5 min each time. The RNA probe was hybridized at 65 °C overnight after prehybridization at 65 °C for 1 h. Chromogenic detection was finished the following day. Samples were first washed three times in 2 × SCC at 65 °C for 15 min each, then rinsed with PBT, blocked for 1 h (20% lamb serum in PBT), and incubated with antibodies for 2 h antibody (DIG-AP, 1:2,000). They were then washed again with PBT and blocked for 10 min with AP. Slides were developed in NBT/BCIP in the dark overnight. The reaction was stopped by AP buffer once the signal had developed. See Supplementary table 2 for a list of antibodies.
For H&E staining, slides were first deparaffinized by three 3-min rounds of xylene, 100% EtOH, 95% EtOH, 80% EtOH, and 70% EtOH. They were stained with hematoxylin for 5 min, then rinsed with tap water until the color change stopped, and dipped in acidic solution (1% HCl in 70% EtOH) two or three times to reduce the background. After rinsing with tap water, they were stained with eosin for 1 min and rinsed again. Finally, they were dehydrated by three rounds of 5 min each in 95% EtOH, 100% EtOH, and xylene.
For IHC, the deparaffinization process was the same as H&E staining. Antigen retrieval was performed by microwaving samples for 10 min using sodium citrate at pH 6.0. Endogenous peroxidases were blocked using 3% H 2 O 2 . After 1 h of serum blocking, slides were incubated with the relevant antibody overnight in a cold room (37-40 °F or 2.8-4.4 °C). The next day, slides were rinsed in PBS and incubated with the secondary antibody for 1 h. DAB and hematoxylin were applied for the color matrix and counterstaining. Finally, they were dehydrated using the same process as used for H&E staining. Antibodies used for immunohistochemical analysis are listed below in the "Antibodies" section.
chromatin immunoprecipitation (chIP)/co-immunoprecipitation (co-IP).
Mouse E12.5 spinal cords were dissected, dissociated, and processed for ChIP or co-IP assays. Similarly, the electroporated half of chick spinal cords were dissected and processed for ChIP or co-IP assays. Five E12.5 mouse dissected spinal cords and seven chick electroporated spinal cord halves per immunoprecipitation and control IgG reaction were used for the assays. For ChIP assays, harvested cells were washed in PBS buffer and fixed with 1% formaldehyde for 10 min at room temperature (68-75 °F or 20.0-23.8 °C). Control regions for ChIP assay correspond to intronic sequences within NFIA devoid of predicted Sox9, Brn2, Lhx3, or Isl1 binding sites. Cells were washed with buffer I (10 mM EDTA, 0.5 mM EGTA, 0.25% Triton X-100, 10 mM HEPES; pH6.5), then buffer II (0.2M NaCL, 1 mM EDTA, 0.5 mM EGTA, 10 mM HEPES; pH6.5). Cells were resuspended in lysis buffer (0.5% SDS, 5 mM EDTA, 25 mM Tris-HCl; pH8.0; protease inhibitors), and sonicated 10 times for 10 s each. Supernatants were then collected and diluted five times in dilution buffer (2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 20 mM Tris-HCl; pH8.0; protease inhibitors), followed by an immunoclearing step with 1 µg of salmon sperm DNA, IgG, and protein G agarose beads (Santa Cruz Biotechnology). Next, the cell lysates were subject to immunoprecipitation using a specific antibody and protein G agarose beads for 8 h to overnight, followed by 10 min washing steps with TSE I buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl; pH8.0), TSE II buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl, 20 mM Tris-HCl; pH8.0), buffer III (0.25M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl; pH8.0), and TE buffer. Genomic DNA fragments were eluted in elution buffer (1% SDS, 0.1 M NaHCO 3 ), followed by incubation at 65 °C overnight to reverse cross-linkage, and treated with proteinase K (Promega) at 42 °C for 2 h. Lastly, genomic DNA fragments were purified using phenol/chloroform, and the DNA pellet was resuspended in water. For ChIP-qPCR, ChIP DNA was analyzed by quantitative PCR (Roche Lightcycler 480) using PerfeCta SYBR Green Fastmix (Quanta Biosciences) according to manufacturer's instructions. The PCR program used was as follows: 5 min at 95 °C followed by 45 cycles of 5 s at 95 °C, 15 s at 57 °C, and 10 s at 72 °C. PCR was performed using region-specific primers listed in Supplementary table 1. All ChIP experiments were performed independently at least twice. See Supplementary table 1 for lists of primer sequences.
For co-IP assays, harvested cell lysates were subject to immunoprecipitation using a specific antibody or IgG control and protein G agarose beads for at least 2 h an up to overnight, followed by multiple washing steps with the lysis buffer supplemented with 300 mM NaCl. The bound proteins were eluted by heating the beads in an SDS gel-loading buffer (50 mM Tris-Cl pH6.8, 100 mM DTT, 2% SDS, 10% glycerol, 0.1% bromophenol blue) at 95 °C for 5 min. Eluted proteins were resolved by SDS-PAGE and visualized by western blotting. Antibodies used for western blot detection are listed in Supplementary table 2.
Antibodies. The antibodies used for ChIP, western blot, and immunofluorescence are listed in Supplementary table 2. chromatin conformation capture assay (3c). The 3C-qPCR assays were performed as previously described 24 . Briefly, E12.5 mouse spinal cords or tumors were dissected and dissociated by papain treatment. Cells were washed with 1× PBS and passed through a cell strainer to obtain single-cell suspensions. Cells were counted and divided into samples containing 10 × 10 6 cells per sample. These cells were cross-linked with 1% formaldehyde for 10 min, followed by cell lysis and isolation of nuclei. Nuclei were digested with 400 U of EcoRI overnight at 37 °C. Digestion efficiency was determined as described in Hagege et al. 24 using a series of primers that detect cutting across all fragments tested in our assay.
Samples that digested at 70% efficiency or greater were used in these studies; samples not meeting minimum digestion efficiency were discarded. Digested samples were then subjected to ligation under conditions favoring intramolecular ligation events. Cross-links were then reversed by heating at 65 °C. The 3C ligation products were purified and subjected to qPCR analysis. Long-range chromatin interactions were detected using locus-specific primers that amplify individual ligation junctions. Unidirectional primers were designed so that all fragments were compared to the anchor primer located in the e123 region or the promoter region. Use of unidirectional primers circumvented the issue of noninformative ligation product amplification. Primers were designed so that they were located within 50-100 bp of the restriction sites, thereby limiting amplicon size to under 250 bp. Control primers to GAPDH and EccR3 were also used for normalization and standard curve generation. Primers were designed using 3C primer design software. A control library was generated from RP23 Bac clones purchased from BACPAC Resource Center (https://bacpacresources.org/) that encompassed the genomic regions examined in this study (RP23-56E9 chr4: 97,609,825-9,785,900). The library was prepared by digesting (EcoRI) and ligating the non-cross-linked BAC-purified DNA. Quantitative PCR was performed on a Lightcycler 480 apparatus (Roche) (5 min at 95 °C followed by 45 cycles of 5 s at 95 °C, 15 s at 57 °C, and 10 s at 72 °C) using PerfeCta SYBR Green Fastmix (Quanta Biosciences). Three independent libraries were assayed per experiment. Primers used for digestion efficiency and long-range interaction detection are listed in Supplementary tables 3 and 4.
In utero electroporation (IUe) and mouse models of glioma. To generate mouse gliomas, we performed in utero electroporation (IUE) as previously described 35 . Briefly, the uterine horns were exposed, and DNA combination was injected into the embryonic lateral ventricles along with Fast Green dye as the indicator. Then electroporation was accomplished with BTW Tweezertrodes connected to the pulse generator (BTX 8300), set at 33 V and 55 ms per pulse six times at 100-ms intervals. In the CRISPR/IUE model, the DNA combination was composed of the helper plasmid pGLAST-PBase (2.0 µg/µL) and all other DNA (1.0 µg/µL), including pbCAG-GFP, pbCAG-Luciferase, crNF1, crPTEN, and crp53 31, 35 . In the PB-Ras/IUE model, the DNA combination is composed of pGLAST-PBase (2.0 µg/µL) and others (1.0 µg/µL), including pbCAG-GFP2aHRas and pbCAG-Luciferase. To measure the tumor growth via bioluminescent imaging, d-luciferin (PerkinElmer, #122799) was diluted to 15 mg/mL with PBS and injected into each mouse at a dose of 10 µL/g body weight. After 10 min, mice were placed inside a Bruker FX Pro Imager for 2 min of bioluminescence imaging and 10 s of X-ray imaging. The X-ray image was transparently overlapped with the bioluminescence image. A free circle surrounded the region of interest (ROI) was selected for the quantification of the luciferase intensity. Relative luciferase intensity was measured against the intensity of control group, which was normalized as 1, such that the experiment group = (actual value of experiment group)/(the actual value of control group).
Animals were killed for analysis at P14 and brains were fixed in 4% paraformaldehyde or 4% formalin. After fixation, brains were embedded in paraffin or OCT, sectioned, and subjected to molecular and/or pathological analysis via immunostaining or H&E staining.
sgRnA sequences and sequencing. Guide sequences were generated using an online program (http://crispr.mit.edu) as previously described by Hsu et al. 37 . Guide sequences were cloned into the pX330 plasmid (Addgene, plasmid 42230). The following guide sequences were used for mouse: e123-1: 5′-CTCATCACGCAATATATGTT-3′; e123-2: 5′-CTCTGATTTAACTGTCAGTC-3′; e161-1: 5′-CTCAAATGAAAGTCGCGATG-3′; and e161-2: 5′-GAAAGTGATCTTGCGATGCT-3′. Plasmids were co-electroporated with helper and donor plasmids at E16 for IUE. Animals were killed for analysis at P14, and tumors were resected and subjected to genomic DNA isolation using DNeasy Blood and Tissue Kit (Qiagen) for sequencing. At least three individual tumors were used for sequencing analysis. Genomic specific primers were used to amplify amplicons surrounding the putative CRISPR-CAS9 modified sites from genomic DNA derived from ∆123/∆161 tumors. The targeted genomic areas flanking sgRNA binding sites were PCR amplified using Phusion High-Fidelity DNA Polymerase (NEB M0530S) and the following primers:
e123: forward, 5′-GAATTATGACAATGGGGTACTTGG-3′; reverse, 5′-GGGGATATGCTACAGTTGGA-3′; and e161: forward, 5′-GTTGTGAAAGAGTCAGCCCC-3′; reverse, 5′-CAAAGGAGAGGTTTACACAAGC-3′. PCR products were purified using Ampure XP magnetic beads at 1.8× volume to separate amplicons from primers and were inspected using the dsDNA 900 Reagent Kit (DNF-900-K0500, AATI) on an Advanced Analytical 12-Capillary Fragment Analyzer. The verified product was then tagmented, amplified, and cleaned up using the Nextera XT DNA Library Prep Kit (FC-131-1024, Illumina). The resulting library was validated using the Standard Sensitivity NGS Fragment Analysis Kit on a 12-Capillary Fragment Analyzer, and samples were normalized to 2 nM using Ampure XP bead-based normalization. Samples were sequenced on an Illumina NextSeq550 following the manufacturer's instructions. Subsequently, reads were aligned to reference sequences of the PCR amplicons and evaluated for the presence of genomic alterations using a custom script 32 . See Supplementary  Figure 9 for schematics.
Statistical methods and data availability.
ANOVA was used to analyze the 3C assays and bioluminescence assays to determine the differences between group means. Student's two-tailed t tests were used to compare individual means and are reported as asterisks in associated figure graphs. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications 17, 18 . Data collection and analysis were not performed blind to the conditions of the experiments. Data distribution was assumed to be normal, but this was not formally tested. Randomization of animal studies was used in the data analysis. Data collection and analysis were not performed blind to the conditions of the experiments. No animal or data points were excluded from the analyses. Descriptive statistics and parameters for individual figures are detailed in Supplementary table 5. Please also see the life Sciences Reporting Summary. The data that support the findings of this study are available from the corresponding author upon reasonable request.
